Numerous studies indicated that testing mitochondrial potential and expression of acetyl-CoA carboxylase α (ACACA) might serve as a predictive target and a therapeutic method in the near future. More in-depth research about ACACA in cancers will help examine and detail the roles of the ACACA in cancer initiation, progression, and development. Nowadays, Creative Biolabs provides a comprehensive set of ACACA analysis service for global clients.
Background
Acetyl-CoA carboxylases (ACCs) are enzymes that catalyze the carboxylation of acetyl-CoA to produce malonyl-CoA. Acetyl-CoA carboxylase α (ACC1), also known as ACACA, is the major member of ACCs in mammalian. ACACA is highly enriched in adipogenic tissues. ACACA localizes in the cytosol and takes the major responsibility of converting cytoplasmic acetyl-CoA into malonyl-CoA for fatty acid synthesis. As Figure 1 shown, ACACA contains three major functional domains: a biotin carboxylase domain (BC domain), a carboxyl transferase domain (CT domain), and a biotin carboxyl carrier protein domain (BCCP domain).
Fig.1 Schematic representation of ACC1 architecture and the roles of its three principal domains.1
Dysregulation of ACCs in Diseases
An increasing number of recent studies focused on the role of ACACA in tumors.
- ACACA as an antitumor target of citrus lemon-derived nanovesicles in colon cancer.
- ACACA is essential for breast cancer cell survival.
- ACACA was overexpressed in liver cancer and contributed to the proliferation of human hepatoma G2 cells and the rat liver cell line BRL3A.
- ACACA was vital in prostate cancer, and the down-regulation of ACACA suppressed prostate cancer through inhibiting mitochondrial potential. The expression level of ACACA was higher in patients with prostate cancer than in healthy controls.
ACCs-Targeting Small Molecules
With the evidence of ACCs participating in the progression of diseases and its structural information, numerous screenings for ACCs antagonists are performed. As Figure 2 shown, the ACCs inhibitors mainly target its BC domain and CT domain. The development of agonists that are specifically against ACC1 might be a promising strategy to target ACCs for diseases treatment.
Fig.2 ACCs inhibitors and its MOA. (Wang, 2022)
Services at Creative Biolabs
Creative Biolabs possesses antibodies that can be used in several scientific applications, including WB, IHC, ICC, and ELISA for ACACA detection use. Our popular services targeting ACACA include but not limited to the following:
- qRT-PCR and WB Analysis
- Cell cycle analysis
- In vivo tumor formation assays
- ELISA Assay
Ready to take your biomarker research to the next level? Get in contact with our experts - We are happy to answer any question! Please feel free to contact us for more information.
Reference
- Wang, Yu, et al. "Acetyl-CoA carboxylases and diseases." Frontiers in oncology 12 (2022): 836058. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
